AKBA
Akebia Therapeutics
$0.77
+$0.11 (+15.91%)Oct 28, 2026
Key metrics
The numbers that frame AKBA today
- Market cap
- $211.99M
- EV / FCF
- 2.7
- Gross margin
- 79.6%
- EV / Sales
- 0.5
- ROIC
- -36.6%
- Div yield
- 0%
- Debt / equity
- 2.2
- 52wk Low
- $0.54
- 52wk High
- $3.20
Growth
Revenue and earnings trend for AKBA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about AKBA
Is Akebia Therapeutics a good buy?
Hold. Akebia Therapeutics has excellent quality, but poor momentum makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Akebia Therapeutics is selling at a fair price.
What is the market capitalization of AKBA?
Akebia Therapeutics's market capitalization is $211.99M.
What is the 52-week high for AKBA stock?
The 52-week high for Akebia Therapeutics is $3.20. The current close of $0.77 is 76.1% below that high.
What is the 52-week low for AKBA stock?
The 52-week low for Akebia Therapeutics is $0.54. The current close of $0.77 is 41.1% above that low.
Does AKBA stock pay dividends?
Akebia Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for AKBA?
Akebia Therapeutics's Debt / Equity ratio is 2.16.